The Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy
International Journal of Molecular Sciences · 16.04.2025 · 26 (8) · 3753
DOI: 10.3390/ijms26083753 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.04.2025. Verfasst von Lina Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Szigeti Str. 12, H-7624 Pecs, Hun…. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retina. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Fund, National Brain Research Program, HUN-REN TKI.
Abstract (Originalsprache)
The continuously growing diabetes population is a significant concern with type 2 diabetic retinal disease (T2DRD), which is a leading cause of permanent blindness. However, the underlying pathophysiological mechanism of T2DRD has not yet been fully understood. Pituitary adenylate cyclase-activating polypeptide (PACAP) was first isolated from the ovine hypothalamus based on its stimulating effect on the adenylate cyclase enzyme in anterior pituitary cells. PACAP38 (PACAP with 38 amino acids) activates anti-apoptotic pathways, inhibits pro-apoptotic signaling, and creates an anti-inflammatory environment in the retina. The aim of the present study was to test the possible retinoprotective effect of the topical administration of PACAP38 in a type 2 diabetic animal model induced by a high-fat diet and the intraperitoneally injected low-dose streptozotocin (STZ). Wistar rats were divided into four groups: the control, control + PACAP38, diabetes, and diabetes + PACAP38 groups randomly. Type 2 diabetes was induced with the combination of STZ (30 mg/kg) and a high-fat diet. All rats were treated topically two times a day for 16 weeks: the control + PACAP38 and diabetes + PACAP38 groups were applied with PACAP38 eye drops (1 µg/drop), while the control and diabetes groups were administered using vehicles (artificial tears). The diabetes model was validated by a fasting oral glucose tolerance test (OGTT) and C-peptide ELISA test. Animals were monitored during the whole experiment for the progression of the disease using electroretinography (ERG) and optical coherence tomography (OCT). Post-mortem immunohistochemistry and a vessel analysis were performed in the retina samples after 16 weeks. An OGTT, a C-peptide ELISA test, and the investigation of blood parameters proved the development of type 2 diabetes. Significant differences could be detected in visual function between the two diabetic groups at week 16 (in the a-wave, b-wave, and OP amplitudes), where the diabetes PACAP38-treated group was similar to the control ones. OCT measurements correlated with ERG data, where the total retinal thickness was preserved in the diabetes + PACAP38 group. PACAP38 also protected the microvascular structure in the retina. Topically administered PACAP38 has potent neuroprotective effects against type 2 diabetic retinal disease; therefore, it could be a promising therapeutic approach for the treatment of T2DRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Szigeti Str. 12, H-7624 Pecs, Hungary.
- Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan 430030, China.
- Department of Sports Biology and Kinesiology, University of Pecs, Ifjusag Str. 6, H-7624 Pecs, Hungary.
ORCID-Profile: Balazs Meresz, Hongjie Wang, Tamas Atlasz
Förderung
- National Research, Development and Innovation Fund
- National Brain Research Program
- HUN-REN TKI
- Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary
- Stipendium Hungaricum and China Scholarship Council
Zitieren
APA
Li, L., Patko, E., Szabo, E., Molitor, D., Meresz, B., Reglodi, D., Varga, A., Denes, D., Dai, L., Wang, H., Vaczy, A., & Atlasz, T. (2025). The Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy. International Journal of Molecular Sciences, 26(8), 3753. https://doi.org/10.3390/ijms26083753
Vancouver
Li L, Patko E, Szabo E, Molitor D, Meresz B, Reglodi D, et al. The Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy. International Journal of Molecular Sciences. 2025;26(8):3753. doi:10.3390/ijms26083753
BibTeX
@article{Li2025,
author = {Li, Lina and Patko, Evelin and Szabo, Edina and Molitor, Dorottya and Meresz, Balazs and Reglodi, Dora and Varga, Andras and Denes, Diana and Dai, Lei and Wang, Hongjie and Vaczy, Alexandra and Atlasz, Tamas},
title = {The Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {8},
pages = {3753},
doi = {10.3390/ijms26083753}
}
EUVIMED